脓毒症休克合并呼吸衰竭患者的诱导性低体温(CASS):一项随机对照开放标签试验
CASS试验为随机、对照、开放标签研究,在10个ICU纳入脓毒症休克合并呼吸衰竭的机械通气患者,随机分为常规体温管理组或诱导性低体温组(目标32-34°C持续24小时,随后36-38°C持续48小时)。计划纳入560例,实际纳入436例后因无效终止。低体温组30天死亡率为44.2%(96/217),常规组为35.8%(77/215),差异8.4%(95%CI -0.8至17.6),相对风险1.2(95%CI 1.0-1.6),P=0.07。作者结论认为诱导性低体温不降低死亡率,不应在脓毒症休克患者中使用。
要点
- 在脓毒症休克合并呼吸衰竭的机械通气患者中,诱导性低体温(32-34°C)组30天死亡率44.2%(96/217),常规体温管理组35.8%(77/215),差异未达统计学显著(P=0.07)。
- 该试验因无效提前终止:计划纳入560例,实际纳入436例后终止。
- 作者结论认为诱导性低体温不降低死亡率,并明确表示不应在脓毒症休克患者中使用诱导性低体温。
- 纳入标准包括平均动脉压低于70 mmHg、ICU机械通气、年龄至少50岁、预计ICU停留至少24小时、符合标准后6小时内入组。
- 排除标准包括无法控制的出血、临床重要出血性疾病、近期开放手术、妊娠或哺乳、非自愿精神科入院。
适用人群与场景
- 严重脓毒症或脓毒症休克患者,纳入标准为平均动脉压低于70 mmHg、ICU机械通气、年龄至少50岁、预计ICU停留至少24小时、符合纳入标准后6小时内入组。
- 排除标准为无法控制的出血、临床重要出血性疾病、近期开放手术、妊娠或哺乳、非自愿精神科入院。
处置流程与药物剂量
- 诱导性低体温组:目标核心体温32-34°C持续24小时,随后36-38°C持续48小时。
- 常规体温管理组:按常规体温管理。
研究设计与关键结果
- 研究类型:随机、对照、开放标签试验,10个ICU,欧洲和北美3个国家,纳入436例(计划560例,因无效提前终止)。
- 主要终点30天全因死亡率(改良意向治疗人群):低体温组44.2%(96/217) vs 常规体温管理组35.8%(77/215),差异8.4%(95%CI -0.8至17.6),相对风险1.2(95%CI 1.0-1.6),P=0.07。
- 主要终点评估者对结局设盲,实施干预的患者和医护人员未设盲。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),开放标签,因无效提前终止。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为:在脓毒症休克合并呼吸衰竭的机械通气患者中,诱导性低体温不降低死亡率;诱导性低体温不应在脓毒症休克患者中使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Animal models of serious infection suggest that 24 h of induced hypothermia improves circulatory and respiratory function and reduces mortality. We tested the hypothesis that a reduction of core temperature to 32-34°C attenuates organ dysfunction and reduces mortality in ventilator-dependent patients with septic shock.
METHODS: In this randomised, controlled, open-label trial, we recruited patients from ten intensive care units (ICUs) in three countries in Europe and North America. Inclusion criteria for patients with severe sepsis or septic shock were a mean arterial pressure of less than 70 mm Hg, mechanical ventilation in an ICU, age at least 50 years, predicted length of stay in the ICU at least 24 h, and recruitment into the study within 6 h of fulfilling inclusion criteria. Exclusion criteria were uncontrolled bleeding, clinically important bleeding disorder, recent open surgery, pregnancy or breastfeeding, or involuntary psychiatric admission. We randomly allocated patients 1:1 (with variable block sizes ranging from four to eight; stratified by predictors of mortality, age, Acute Physiology and Chronic Health Evaluation II score, and study site) to routine thermal management or 24 h of induced hypothermia (target 32-34°C) followed by 48 h of normothermia (36-38°C). The primary endpoint was 30 day all-cause mortality in the modified intention-to-treat population (all randomly allocated patients except those for whom consent was withdrawn or who were discovered to meet an exclusion criterion after randomisation but before receiving the trial intervention). Patients and health-care professionals giving the intervention were not masked to treatment allocation, but assessors of the primary outcome were. This trial is registered with ClinicalTrials.gov, number NCT01455116.
FINDINGS: Between Nov 1, 2011, and Nov 4, 2016, we screened 5695 patients. After recruitment of 436 of the planned 560 participants, the trial was terminated for futility (220 [50%] randomly allocated to hypothermia and 216 [50%] to routine thermal management). In the hypothermia group, 96 (44·2%) of 217 died within 30 days versus 77 (35·8%) of 215 in the routine thermal management group (difference 8·4% [95% CI -0·8 to 17·6]; relative risk 1·2 [1·0-1·6]; p=0·07]).
INTERPRETATION: Among patients with septic shock and ventilator-dependent respiratory failure, induced hypothermia does not reduce mortality. Induced hypothermia should not be used in patients with septic shock.
FUNDING: Trygfonden, Lundbeckfonden, and the Danish National Research Foundation.
参考来源
- Itenov TS, Johansen ME, Bestle M, et al. Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. Lancet Respir Med. 2018. PMID: 29325753. doi:10.1016/S2213-2600(18)30004-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。